4//SEC Filing
Adimab, LLC 4
Accession 0001209191-21-051295
CIK 0001832038other
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 9:22 PM ET
Size
11.5 KB
Accession
0001209191-21-051295
Insider Transaction Report
Form 4
Adimab, LLC
10% Owner
Transactions
- Conversion
Common Stock
2021-08-10+25,860,700→ 27,845,995 total - Conversion
Series A Preferred Stock
2021-08-10−5,000,000→ 0 total→ Common Stock (25,000,000 underlying) - Conversion
Series C Preferred Stock
2021-08-10−128,064→ 0 total→ Common Stock (640,320 underlying) - Conversion
Series B Preferred Stock
2021-08-10−44,076→ 0 total→ Common Stock (220,380 underlying)
Footnotes (1)
- [F1]Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.
Documents
Issuer
Adagio Therapeutics, Inc.
CIK 0001832038
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001545672
Filing Metadata
- Form type
- 4
- Filed
- Aug 11, 8:00 PM ET
- Accepted
- Aug 12, 9:22 PM ET
- Size
- 11.5 KB